SCHEDULE: Franklin Resources Amends Benitec Biopharma Stake

Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. have filed an amendment to their Schedule 13G, disclosing a 10.6% beneficial ownership in Benitec Biopharma Inc. as of December 31, 2025.

Summary

• Franklin Resources, Inc. and Franklin Advisers, Inc. collectively beneficially own 3,751,709 shares of Benitec Biopharma Inc. Common Stock.
• This ownership represents 10.6% of the total class of securities.
• The reported beneficial ownership includes 1,554,404 shares of Common Stock that are issuable upon the exercise of warrants.
• Franklin Advisers, Inc. holds sole voting power and sole dispositive power over these 3,751,709 shares.
• Franklin Biotechnology Discovery Fund, a sub-fund of Franklin Templeton Investment Funds, has an interest in 2,445,585 shares, which constitutes 6.9% of the class of securities.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Benitec Biopharma Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive update, as it confirms continued significant institutional investment in Benitec Biopharma Inc. by Franklin Resources, indicating ongoing confidence from a major asset manager.

Positives

• Continued significant institutional ownership by Franklin Resources, Inc. and its affiliates, indicating ongoing investment interest in Benitec Biopharma Inc.
• The inclusion of shares issuable from warrants suggests a potential long-term investment perspective or participation in previous financing rounds.

Risks

• The reporting persons disclaim that they are a 'group' within the meaning of Rule 13d-5 under the Securities Exchange Act of 1934, and disclaim beneficial ownership for certain individuals (Charles B. Johnson, Rupert H. Johnson, Jr.) and pecuniary interest for Franklin Resources, Inc. and its Principal Shareholders, which is a standard disclaimer for complex institutional ownership structures.

Future Outlook

na

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which is a standard practice in the biopharma sector where institutional investment often plays a crucial role in funding and validating companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
• Company Management: Awareness of a large, stable institutional holder can impact strategic decisions and investor relations.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership by a major institutional investor. It does not contain new financial performance data, strategic announcements, or material changes in the investment thesis for Benitec Biopharma Inc. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on prior analysis rather than this specific filing.

Keywords

Benitec Biopharma, Franklin Resources, Franklin Advisers, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biopharma, Warrants, SEC Filing